vimarsana.com

Page 14 - டியூக் மருத்துவ ஆராய்ச்சி நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

COVID Showed How Trials for New Drugs Could Be Faster and Better

Scientific American COVID Showed How Trials for New Drugs Could Be Faster and Better The pandemic has spotlighted ways to make clinical trials easier on patients and better for science, a heart drug researcher says Advertisement A dozen years and a billion or more dollars that is what it typically takes to bring a new drug from the lab to your medicine cabinet. Testing medications on patients has become a slow, arduous process. People, even those who are desperate to participate, often have to travel long distances to a study site and make the trip over and over again. For scientists, coordinating the paperwork among a large number of research centers can be extremely laborious and time-consuming.

CDC and NIH launch community COVID-19 testing initiative

CDC and NIH launch community COVID-19 testing initiative The Centers for Disease Control and Prevention (CDC), in collaboration with the National Institutes of Health (NIH), has launched an innovative community health initiative called Say Yes! COVID Test starting in Pitt County, North Carolina, and coming soon to Chattanooga/Hamilton County Tennessee. As many as 160,000 residents across the two communities will have access to free, rapid antigen tests that they can administer themselves to use three times a week for one month. NIH will provide the tests (also called a home-test or at-home test) and evaluate the effectiveness of the initiative, which aims to determine if frequent self-administered COVID-19 testing helps residents reduce community transmission of SARS-CoV-2, the virus that causes COVID-19 disease.

Cerner closes its Kantar Health acquisition, sets sights on life sciences

(Photo courtesy of Cerner) Cerner on Thursday announced the completion of its purchase of Kantar Health for $375 million in cash – an acquisition it says will be a boost to its expanded efforts toward life sciences research capabilities. WHY IT MATTERS Kantar Health s analytics expertise spans a wide array of therapeutic areas: Alzheimer s, cancers, rare diseases and more. Its tools and policy expertise have been used by companies across the pharma and life sciences industries. Cerner says combining those research and consulting bona fides with its own real-world data stores and portfolio of technologies can better help companies and research groups develop new therapeutics and improve health, wellness and treatment outcomes.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.